CN111686237A - 一种防治心血管疾病的心肌肽金丝小枣制剂及其制备方法 - Google Patents
一种防治心血管疾病的心肌肽金丝小枣制剂及其制备方法 Download PDFInfo
- Publication number
- CN111686237A CN111686237A CN202010485886.9A CN202010485886A CN111686237A CN 111686237 A CN111686237 A CN 111686237A CN 202010485886 A CN202010485886 A CN 202010485886A CN 111686237 A CN111686237 A CN 111686237A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- silk jujube
- water
- cardiovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 39
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 34
- 210000004165 myocardium Anatomy 0.000 title claims description 6
- 240000008866 Ziziphus nummularia Species 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 241001247821 Ziziphus Species 0.000 claims abstract description 32
- 230000002107 myocardial effect Effects 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 28
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 18
- 238000010438 heat treatment Methods 0.000 claims abstract description 17
- 241000411851 herbal medicine Species 0.000 claims abstract description 17
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims abstract description 14
- 238000001816 cooling Methods 0.000 claims abstract description 12
- 241000208966 Polygala Species 0.000 claims abstract description 11
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 11
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 230000001954 sterilising effect Effects 0.000 claims abstract description 7
- 238000011049 filling Methods 0.000 claims abstract description 6
- 235000013599 spices Nutrition 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 241000488974 Loranthus Species 0.000 claims description 9
- 230000003071 parasitic effect Effects 0.000 claims description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 8
- 244000179560 Prunella vulgaris Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 235000008113 selfheal Nutrition 0.000 claims description 8
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 7
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 241000132012 Atractylodes Species 0.000 claims description 6
- 244000104272 Bidens pilosa Species 0.000 claims description 6
- 235000010662 Bidens pilosa Nutrition 0.000 claims description 6
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 6
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 6
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 6
- 240000000171 Crataegus monogyna Species 0.000 claims description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 6
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 6
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 6
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 6
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 6
- 235000011201 Ginkgo Nutrition 0.000 claims description 6
- 244000194101 Ginkgo biloba Species 0.000 claims description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 6
- 240000000249 Morus alba Species 0.000 claims description 6
- 235000008708 Morus alba Nutrition 0.000 claims description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims description 6
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 6
- 241001522129 Pinellia Species 0.000 claims description 6
- 244000046146 Pueraria lobata Species 0.000 claims description 6
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 6
- 241000202726 Bupleurum Species 0.000 claims description 4
- 241000305492 Gastrodia Species 0.000 claims description 4
- 241000305491 Gastrodia elata Species 0.000 claims description 4
- 241000212322 Levisticum officinale Species 0.000 claims description 4
- 239000001645 levisticum officinale Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 241000112528 Ligusticum striatum Species 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims 1
- 244000126002 Ziziphus vulgaris Species 0.000 claims 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 46
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- 230000036772 blood pressure Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 15
- 230000000747 cardiac effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 230000003860 sleep quality Effects 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- 230000002526 effect on cardiovascular system Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种防治心血管疾病的心肌肽金丝小枣制剂,属于医药技术领域,包括以下重量份数的物质:心肌肽粉2.5‑8.5份、金丝小枣8.0‑16.0份、γ‑氨基丁酸0.3‑4.6份和中草药粉末,所述中草药包括远志0.3‑3.0份、金银花0.3‑3.0份、柴胡0.2‑2.5份和虎杖0.2‑2.5份,余量为水。并通过以下步骤制得:水浴锅中边搅拌边加热、保温、降温、过滤,滤渣放回水浴锅中进行溶解反应,然后趁热过滤,得到滤液,弃去滤渣,滤液混合,加热,保温,通入冷凝水迅速降温至25℃,匀质5分钟;最后加入香料,再搅拌混匀,调节PH为5.5‑6.0,检测,灌装,灭菌得成品。本发明得到的心肌肽金丝小枣制剂具有多重功效,降压、降血脂还能改善睡眠提高身体质量,达到全面治疗和预防心血管疾病的作用,且成分安全,不含防腐剂。
Description
技术领域
本发明涉及医药技术领域,具体属于一种预防或治疗心血管疾病的制剂及其制备方法。
背景技术
心脑血管疾病是心脏血管和脑血管疾病的统称,泛指由于高脂血症、血液黏稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生的缺血性或出血性疾病。心脑血管疾病是一种严重威胁人类,特别是50岁以上中老年人健康的常见病,具有高患病率、高致残率和高死亡率的特点,即使应用目前最先进、完善的治疗手段,仍可有50%以上的脑血管意外幸存者生活不能完全自理,全世界每年死于心脑血管疾病的人数高达1500万人,居各种死因首位。
然而对于心血管疾病发病机制复杂,临床上常见的治疗心血管疾病的药物如钙离子通道阻断剂,长期服用会产生头晕、心跳加快等不良反应。西药通常为单靶点治疗,这种治疗方式见效果快,但是西药治疗通常还会有较大的副作用。近年来对中医的研究逐渐重视起来,中医注重根本,采用天然中草药或者复方药物进行治疗,副作用低,但是疗程久、耗时长,见效慢,难以长期坚持。
另外,心血管预防和治疗上基本都是单一功效的药物或者制剂,不但效果不佳,还容易反复,无法从整体上调理,解决问题。目前对心血管疾病的治疗,通常是一种病症使用一种药物,而心血管疾病患者容易产生多种并发症,这就需要服用多种药物进行治疗和控制,从而产生不少的副作用,病情还容易反复还,整体疗效并不理想。另外心血管疾病患者大多为老年人,身体较弱,服用过多的药物还会导致身体质量不断下降,从而形成恶性循环。
发明内容
针对背景技术中存在的缺陷和不足,本发明提供了一种防治心血管疾病的心肌肽金丝小枣制剂,具有多重功效,能够降压、降血脂还能改善睡眠提高身体质量,达到全面治疗和预防心血管疾病的作用,且成分安全,不含防腐剂。
本发明的目的之二是提供一种防治心血管疾病的心肌肽金丝小枣制剂的制备方法,能够保持各物质的活性,使得制备出的心肌肽金丝小枣制剂能够发挥出最佳的协同作用,去除成分的刺激性,保持成分的活性。
为实现上述目的,本发明采用以下技术方案予以实现:
一种防治心血管疾病的心肌肽金丝小枣制剂,包括以下重量份数的物质:
心肌肽粉2.5-8.5份、金丝小枣8.0-16.0份、γ-氨基丁酸0.3-4.6份和中草药粉末,余量为水;
所述中草药包括远志0.3-3.0份、金银花0.3-3.0份、柴胡0.2-2.5份和虎杖0.2-2.5份。
进一步所采取的措施是:所述中草药还包括桑寄生0.2-0.6份、山药0.5-2.5份、银杏叶0.1-0.8份、决明子0.6-2.0份、沙棘果0.1-0.6份、桑叶0.5-1.5份、山楂0.5-1.5份、三七0.2-1.0份、葛根0.2-1.0份、夏枯草0.2-1.0份、野菊花0.2-1.0份、川芎0.1-0.9份、天麻0.1-0.9份、半夏0.2-1.0份、白术0.2-1.0份、鬼针草0.2-0.6份。
进一步所采取的措施是:包括以下重量份数的物质:心肌肽粉4.0-8.5份、金丝小枣10.5-14.5份、γ-氨基丁酸2.5-4.2份、远志1.5-2.5份、金银花1.5-3.0份、柴胡1.6-2.5份、虎杖1.5-2.5份、桑寄生0.4-0.5份、山药1.5-2.2份、银杏叶0.3-0.7份、决明子1.2-1.8份、沙棘果0.4-0.6份、桑叶0.2-1.4份、山楂1.0-1.4份、三七0.5-0.9份、葛根0.8-1.0份、夏枯草0.4-0.9份、野菊花0.4-0.8份、川芎0.4-0.6份、天麻0.4-0.6份、半夏0.7-0.9份、白术0.7-0.8份、鬼针草0.3-0.6份。
进一步所采取的措施是:包括以下重量份数的物质:心肌肽粉8.5份、金丝小枣14.5份、γ-氨基丁酸4.0份、远志2.5份、金银花2.2份、柴胡2.5份、虎杖2.5份、桑寄生0.4份、山药2.0份、银杏叶0.6份、决明子1.8份、沙棘果0.4份、桑叶0.9份、山楂1.2份、三七0.5份、葛根0.9份、夏枯草0.9份、野菊花0.8份、川芎0.4份、天麻0.4份、半夏0.7份、白术0.7份、鬼针草0.3份,余量为水。
进一步所采取的措施是:所述心肌肽粉、金丝小枣与γ-氨基丁酸三者的质量份数的比值为1:(1.6-2.6):(0.4-0.6)。
进一步所采取的措施是:所述远志、金银花、柴胡和虎杖的总质量份数为6.1-9.7份。
进一步所采取的措施是:所述中草药粉末均为经过中药材专用粉碎设备微粉化后的超微粉末。
进一步所采取的措施是:还包括食品用香料0.05-0.12份。
一种防治心血管疾病的心肌肽金丝小枣制剂的制备方法,包括以下步骤:
S1:将相应份数的中草药粉末和一半相应份数的水加入水浴锅中,边搅拌边加热至92-96℃,然后保温40-60min,降温至60-65℃,进行过滤,得到滤液A待用,滤渣A放回水浴锅中;
S2:在放滤渣A的水浴锅中加入醋酸5-8ml和剩余的另一半水,边搅拌边水浴加热至85℃,静置保温10min,然后继续加热至98-100℃,保持高温搅拌20-30分钟,然后趁热过滤,得到滤液B,弃去滤渣;
S3:将心肌肽粉和金丝小枣放入匀质搅拌锅中,匀质3min,然后放入滤液A和滤液B进行混合,并加热至45-50℃,保温10分钟,然后停止加热,通入冷凝水迅速降温至25℃,加入相应份数的γ-氨基丁酸,匀质5分钟。
S4:最后加入香料,再搅拌混匀,调节PH为5.5-6.0,检测,灌装,灭菌得成品。
进一步所采取的措施是:所述步骤S4中,采用真空灌装后,通过高温热水喷淋,在100℃的环境下,灭菌10分钟;然后冷风进行缓慢降温。
本发明从提高心血管疾病患者身体质量的研究方向出发,而改善失眠,提高睡眠质量,就是提高身体素质,增强抵抗力的一个重要突破口。所以本发明立足于降压、降血脂进行治疗和预防心脑血管疾病,同时注重提高睡眠质量,从而提高身体整体质量,综合进行治疗和预防心血管疾病。
其中,心肌肽:是心肌细胞内参与维持生理pH值稳定的重要物质之一,可产生内源性心肌保护,直接作用于心肌细胞,通过调动心肌细胞自身代谢功能,提高耐受能力,达到细胞保护、损伤修复的效果。具有靶向性的特点,能够精准对心肌细胞进行营养,给心肌细胞提供日常所需的能量及营养物质。
金丝小枣:具有丰富的营养价值和药用价值,可滋补身体和辅助治疗脾胃虚弱,消化不良,肺虚咳嗽,贫血等病症的功能,具有维持毛细血管通透性,改善微循环从而预防动脉硬化的作用。还可以调节人体代谢、增强免疫力、抗炎、抗变态反应、降低血糖和胆固醇含量等作用;所含芦丁有保护毛细血管通畅、防止血管壁脆性增加。还含有丰富的维生素C、维生素P,对健全毛细血管、维持血管壁弹性,抗动脉粥样硬化很有益。药理作用表现为改善人体微循环,扩张冠状动脉,增加脑和心脏的供血量,减慢心律,降低心肌耗氧量而改善缺血心肌的代谢,可防治心脑血管病。
γ-氨基丁酸:是中枢神经系统中很重要的抑制性神经递质,具有镇静神经、抗焦虑、有镇静、催眠、抗惊厥,以及降低血压、降低血氨的生理作用,还能促进睡眠,美容润肤,延缓脑衰老机能,促进肾机能改善和保护作用。它抑制脂肪肝及肥胖症,活化肝功能,促进人体内氨基酸代谢的平衡,调节免疫功能。
远志:味辛苦,性微温,归肺经、心经、肾经。养生保健中,借其安神益智之力、祛痰解郁之功,以治疗惊悸、健忘、梦遗、失眠、咳嗽多痰之症,外用治疗疮疖痈疽。还具有抗氧化、抗衰老的作用,对中枢降压的作用。以及活血、抗炎、抗菌和提高抵抗力。
虎杖:抗病原微生物,对多种病毒有抑制作用,对呼吸系统的影响,还有镇咳作用,还有降压、减慢心率、加强心肌收缩力、保护心脏、抑制血小板聚集、改善血液流变学、改善微循环、升高白细胞及血小板、抗休克的作用,还有镇静、镇痛的作用,还有止血、抗肿瘤、降血糖、降血脂、抗炎、抗氧化的作用。
沙棘果:含有多种维生素、脂肪酸、微量元素、亚油素、沙棘黄酮、超氧化物等活性物质和人体所需的各种氨基酸,可降低胆固醇,治愈心绞痛等,还有防治冠状动脉粥样硬化
桑寄生:苦能燥,甘能补,祛风湿又长于补肝肾、强筋骨,对痹证日久,伤及肝肾,腰膝酸软,筋骨无力者尤宜,能补肝肾,养血而固冲任,安胎,治肝肾亏虚,月经过多,崩漏,妊娠下血,胎动不安者,还能降血压,可用于高血压病。
心肌肽粉虽有靶向作用,用于治疗心血管疾病,但是疗效短暂。发明人着眼于对心血管疾病的根源、人体预防和抵抗的整体研究,将心肌肽粉与金丝小枣搭配,并辅以γ-氨基丁酸,产生了令人优异的降压降脂的效果,但是对调了整体功效上仍有欠缺。心血管疾病患者大多为老年人,为提升身体素质,促进睡眠质量,才能提高整体的抵抗能力。发明人继续深入研究心肌肽、金丝小枣的特性,不断尝试不同的搭配成分和搭配策略,最终寻找到一种平时在疗效上并不突出的中草药---志远。但是志远在这里却发挥出了优异的舒缓神经、促进睡眠的功效,同时抗氧化,消除自由基,促进新陈代谢的作用。
另外,再用桑寄生搭配天麻、决明子、夏枯草,互为补充,发挥出最佳的协同作用。利用桑寄生调补肝肾,滋养阴血;天麻平肝息风;决明子清肝泻热,夏枯草去肝经实火,达到能滋养肝肾阴血,平肝息风,肝阴得养,肝热得泻,并效缓解上亢之头晕目眩、血压升高、四肢麻木等。
通过上述技术方案,本发明与现有技术相比,所具有的有益效果如下:
1、本发明能够改善心血管疾病患者的血压、血脂和睡眠情况,并且成分安全,不会产生毒副作用,也不含有防腐剂,具有全面改善身体质量,有效预防和治疗心血管疾病的效果。
2、本发明的制备方法,能够保持各物质的活性,同时促进成分间的反应,去除成分的刺激性,使得制备出的心肌肽金丝小枣制剂能够发挥出最佳的协同作用。
具体实施方式
为了更清楚的了解本发明所采用的技术方案,下面对本发明的优选实施例进行说明,应当理解,此处所描述的实施例仅用于说明和解释本发明,并不用于限定本发明。
实施例1-7:一种防治心血管疾病的心肌肽金丝小枣制剂,所包含的具体成分及相应重量份数如下表1所示:
表1:各实施例的成分及相应份数明细
通过以下制备方法制得,包括以下步骤:
S1:将相应份数的中草药粉末和一半相应份数的水加入水浴锅中,边搅拌边加热至92-96℃,然后保温40-60min,降温至60-65℃,进行过滤,得到滤液A待用,滤渣A放回水浴锅中;
S2:在放滤渣A的水浴锅中加入醋酸5-8ml和剩余的另一半水,边搅拌边水浴加热至85℃,静置保温10min,然后继续加热至98-100℃,保持高温搅拌20-30分钟,然后趁热过滤,得到滤液B,弃去滤渣;
S3:将心肌肽粉和金丝小枣放入匀质搅拌锅中,匀质3min,然后放入滤液A和滤液B进行混合,并加热至45-50℃,保温10分钟,然后停止加热,通入冷凝水迅速降温至25℃,加入相应份数的γ-氨基丁酸,匀质5分钟。
S4:最后加入香料,再搅拌混匀,调节PH为5.5-6.0,检测,采用真空灌装,并通过高温热水喷淋,在100℃的环境下,灭菌30分钟;然后冷风进行缓慢降温,得成品。
其中:心肌肽粉为猪心肌肽粉或者牛心肌肽粉;
金丝小枣为采购于乐陵的金丝小枣;
γ-氨基丁酸为河北鸿韬生物工程有限公司的食品级γ-氨基丁酸;
中草药微粉化所用设备为深圳雷粤机械设备有限公司的中药材专用粉碎设备,型号为ZD-20L。经过微粉化得到的中草药超微粉能够更好的发挥各成分的功效,也使得各种活性物质间能够得到充分的反应,有助于提升整体的的功效。
在步骤3中需要通入冷凝水迅速降温至25℃,可以避免加入γ-氨基丁酸的时候温度过高,还能保护心肌肽粉和金丝小枣中的活性成分。另外,灭菌时应注意温度和时间的控制,热水喷淋有助于温度均匀,而冷风缓慢降温,避免过快冷却,有利于保护制剂的稳定性。
食用方法:将本品加入适量温开水稀释后饮用。
注意:开瓶后立即饮用,若有少许沉淀分层,属于正常现象。
针对本发明实施例得到的制剂进行毒性实验,以下是试验控制条件及过程。
急性毒性试验:选取80只同一批次,体重在20-28g的健康小鼠,随机进行分组,每组10只,共8组分别对应进行上述1-8实施例成品制剂的毒性试验,整个实验过程中全部试验小鼠喂养相同的饲料和水,饲养环境相同。
(1)对各组别小鼠分别采用对应实施例的制剂进行尾部静脉注射给药,给药剂量为10ml/Kg,给药后观察7天。
结果:7天内,无一小鼠死亡,也无异样出现。
(2)加大剂量,第8天对各组别小鼠分别采用对应实施例的制剂进行尾部静脉注射给药,给药剂量为15ml/Kg,给药后观察7天。
结果:14天内,无一小鼠死亡,也无异样出现。
(3)再加大剂量,第15天对各组别小鼠分别采用对应实施例的制剂进行尾部静脉注射给药,给药剂量为20ml/Kg,给药后观察14天。
结果:28天内,无一小鼠死亡,也无异样出现。
经过三次急性毒性试验,逐渐加大剂量,同时控制其他条件相同,最终结果,小鼠并无出现异常,因此本发明的试剂无毒无害,成分安全。
长期毒性试验:选取80只同一批次,体重在100±10g的健康大鼠,随机进行分组,每组10只,共8组,整个实验过程中全部试验大鼠喂养相同的饲料和水,饲养环境相同。给各组大鼠分别采用本发明1-8实施例的成品制剂进行尾静脉注射给药,给药剂量为10ml/Kg,每日上午给药一次,连续给药60天,注意每日给大鼠测量体重,然后根据体重调整给药的剂量,并记录下大鼠每天的发育和健康状态。
60天后,停药观察30天,期间记录小鼠的状态,然后每组随机挑选2只大鼠处死,取血做血常规和血液生化指标的测定,并进行解刨,对大鼠的脏器进行病理组织学检查,剩余大鼠直接处死。
结果表明,给药60天,外加观察30天后,试验的大鼠无一死亡,并且体重正常增加;对每组大鼠的血常规和血液生化指标的测定均显示正常,且大鼠的脑、心、肝、脾、肾、胸腺、肠胃等均发育正常,未见异常。这表明,本发明制剂长期使用也无毒副作用,安全性良好。
临床效果试验:完成毒性试验,且结果均显示安全无毒副作用后,针对以上实施例1-8的成品制剂与市场上采购的对照样1常规治疗心血管疾病的药物和对照样2预防心血管疾病的保健品,进行了临床效果对比试验。
试验控制条件和过程如下:
在同一地区,同一时间段,征集年龄在45-65岁的男性和女性志愿者共计80名,并随机分为8组,每组10人。每一位志愿者均患有轻度的心血管疾病如高血压、高血脂等,偶有失眠,精神状态稍显疲态,但无其他重病。8组志愿者分别对应使用实施例1-8、对照样例1-2,且在没有不适或者其他身体情况出现时,每组志愿者均使用对应试样作为防治药品,每天上午和晚上各服用一次,每次10ml,持续30天;若有不适或者其他身体情况出现时,则及时就医,参加试验的志愿者每天反馈身体健康情况并量血压反馈结果。汇总30天的试验数据,进行分析,得到试验结果情况如下表2和表3所示。
表2:血压、血脂及睡眠质量对照试验结果
由上表2对比数据结果可以明显看出,本发明的实施例1-8得到的心肌肽金丝小枣口服液相比采购的对照样1常规治疗心血管疾病的药物和对照样2预防心血管疾病的保健品,对治疗和改善血脂、血压和睡眠质量均具有突出的效果,且安全温和,无副作用。
表3是对血压、血脂、睡眠质量和毒副作用的整体效果综合评价结果。其中整体有改善/人是指对血压、血脂和睡眠质量均有改善且无出现副作用的人数;部分有改善/人是指血压、血脂和睡眠质量三项指标中有1-2项指标出现改善的人数;是否出现副作用是指实验过程中,服用试验样品后有无出现过敏或者身体不适甚至变差的试验志愿者。
表3:整体评价及副作用对照试验结果
通过上表3的整体评价情况可以明显看出,本发明1-8实施例心肌肽金丝小枣制剂能够从整体上改善心血管疾病患者的血压、血脂和睡眠的情况,效果优异,并且不会产生副作用,从而达到全面改善身体质量,更好的发挥出预防和治疗心血管疾病的效果。对照样1在降压效果上虽然表现出较好的效果,但是在血脂和睡眠上的改善情况并不佳,甚至还出现副作用,有1例血脂上升,效果更差的情况。
实施例4、6-8实施例的制剂对改善血压、血脂和睡眠质量的效果尤佳,特别是实施例6,是发明人长期研究后,得到的最佳实施例方案。本发明在研究和试验过程中也经历了无数次失败,但坚持在失败的方案、试验中不断总结经验,再结合本发明成功的实施例,特别是实施例4、6-8,得出了心肌肽粉、金丝小枣与γ-氨基丁酸三者的质量份数的比值为1:(1.6-2.6):(0.4-0.6),同时控制远志、金银花、柴胡和虎杖的总质量份数在6.1-9.7份的范围内,能够进一步提升整体的协同功效,且长期使用也不会产生毒副作用,从整体上改善身体的质量,发挥出优异的预防和治疗心血管疾病的效果。
以上所述仅用以说明本发明的技术方案而非限制,本领域普通人员对本发明的技术方案所做的均等修饰与变化,只要不脱离本发明创造整体构思的情况下,均仍属于本发明创造涵盖的范围之中。
Claims (10)
1.一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:包括以下重量份数的物质:
心肌肽粉2.5-8.5份、金丝小枣8.0-16.0份、γ-氨基丁酸0.3-4.6份和中草药粉末,余量为水;
所述中草药包括远志0.3-3.0份、金银花0.3-3.0份、柴胡0.2-2.5份和虎杖0.2-2.5份。
2.根据权利要求1所述的一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:所述中草药还包括桑寄生0.2-0.6份、山药0.5-2.5份、银杏叶0.1-0.8份、决明子0.6-2.0份、沙棘果0.1-0.6份、桑叶0.5-1.5份、山楂0.5-1.5份、三七0.2-1.0份、葛根0.2-1.0份、夏枯草0.2-1.0份、野菊花0.2-1.0份、川芎0.1-0.9份、天麻0.1-0.9份、半夏0.2-1.0份、白术0.2-1.0份、鬼针草0.2-0.6份。
3.根据权利要求2所述的一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:包括以下重量份数的物质:心肌肽粉4.0-8.5份、金丝小枣10.5-14.5份、γ-氨基丁酸2.5-4.2份、远志1.5-2.5份、金银花1.5-3.0份、柴胡1.6-2.5份、虎杖1.5-2.5份、桑寄生0.4-0.5份、山药1.5-2.2份、银杏叶0.3-0.7份、决明子1.2-1.8份、沙棘果0.4-0.6份、桑叶0.2-1.4份、山楂1.0-1.4份、三七0.5-0.9份、葛根0.8-1.0份、夏枯草0.4-0.9份、野菊花0.4-0.8份、川芎0.4-0.6份、天麻0.4-0.6份、半夏0.7-0.9份、白术0.7-0.8份、鬼针草0.3-0.6份。
4.根据权利要求3所述的一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:包括以下重量份数的物质:
心肌肽粉8.5份、金丝小枣14.5份、γ-氨基丁酸4.0份、远志2.5份、金银花2.2份、柴胡2.5份、虎杖2.5份、桑寄生0.4份、山药2.0份、银杏叶0.6份、决明子1.8份、沙棘果0.4份、桑叶0.9份、山楂1.2份、三七0.5份、葛根0.9份、夏枯草0.9份、野菊花0.8份、川芎0.4份、天麻0.4份、半夏0.7份、白术0.7份、鬼针草0.3份,余量为水。
5.根据权利要求1所述的一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:所述心肌肽粉、金丝小枣与γ-氨基丁酸三者的质量份数的比值为1:(1.6-2.6):(0.4-0.6)。
6.根据权利要求1所述的一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:所述远志、金银花、柴胡和虎杖的总质量份数为6.1-9.7份。
7.根据权利要求1所述的一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:所述中草药粉末均为经过中药材专用粉碎设备微粉化后的超微粉末。
8.根据权利要求1所述的一种防治心血管疾病的心肌肽金丝小枣制剂,其特征在于:还包括食品用香料0.05-0.12份。
9.权利要求1-8中任一项所述的一种防治心血管疾病的心肌肽金丝小枣制剂的制备方法,其特征在于:包括以下步骤:
S1:将相应份数的中草药粉末和一半相应份数的水加入水浴锅中,边搅拌边加热至92-96℃,然后保温40-60min,降温至60-65℃,进行过滤,得到滤液A待用,滤渣A放回水浴锅中;
S2:在放滤渣A的水浴锅中加入醋酸5-8ml和剩余的另一半水,边搅拌边水浴加热至85℃,静置保温10min,然后继续加热至98-100℃,保持高温搅拌20-30分钟,然后趁热过滤,得到滤液B,弃去滤渣;
S3:将心肌肽粉和金丝小枣放入匀质搅拌锅中,匀质3min,然后放入滤液A和滤液B进行混合,并加热至45-50℃,保温10分钟,然后停止加热,通入冷凝水迅速降温至25℃,加入相应份数的γ-氨基丁酸,匀质5分钟。
S4:最后加入香料,再搅拌混匀,调节PH为5.5-6.0,检测,灌装,灭菌得成品。
10.根据权利要求9所述的一种防治心血管疾病的心肌肽金丝小枣制剂的制备方法,其特征在于:所述步骤S4中,采用真空灌装后,通过高温热水喷淋,在100℃的环境下,灭菌30分钟;然后冷风进行缓慢降温。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010485886.9A CN111686237A (zh) | 2020-06-01 | 2020-06-01 | 一种防治心血管疾病的心肌肽金丝小枣制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010485886.9A CN111686237A (zh) | 2020-06-01 | 2020-06-01 | 一种防治心血管疾病的心肌肽金丝小枣制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111686237A true CN111686237A (zh) | 2020-09-22 |
Family
ID=72479148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010485886.9A Pending CN111686237A (zh) | 2020-06-01 | 2020-06-01 | 一种防治心血管疾病的心肌肽金丝小枣制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111686237A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101012455A (zh) * | 2005-11-14 | 2007-08-08 | 大连珍奥药业有限公司 | 一种生化物质的灭活方法、一种心肌肽素的制备方法及其用途 |
CN101077365A (zh) * | 2006-05-24 | 2007-11-28 | 捷通国际有限公司 | 用于改善睡眠持续时间和质量的白芍提取物 |
CN101632740A (zh) * | 2008-07-25 | 2010-01-27 | 河北以岭医药研究院有限公司 | 一种调节血脂、改善睡眠的中药组合物及其制备方法 |
CN102327574A (zh) * | 2011-06-20 | 2012-01-25 | 洪伟 | 一种用于治疗冠心病的复方制剂及其制备方法 |
CN105412271A (zh) * | 2015-11-19 | 2016-03-23 | 天津天狮生物发展有限公司 | 一种用于改善睡眠的组合物及其制备方法 |
CN108607091A (zh) * | 2016-12-12 | 2018-10-02 | 锡林郭勒盟肽好生物制品有限责任公司 | 降血压多肽草本固体饮料的配方及心肌肽粉制备方法 |
-
2020
- 2020-06-01 CN CN202010485886.9A patent/CN111686237A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101012455A (zh) * | 2005-11-14 | 2007-08-08 | 大连珍奥药业有限公司 | 一种生化物质的灭活方法、一种心肌肽素的制备方法及其用途 |
CN101077365A (zh) * | 2006-05-24 | 2007-11-28 | 捷通国际有限公司 | 用于改善睡眠持续时间和质量的白芍提取物 |
CN101632740A (zh) * | 2008-07-25 | 2010-01-27 | 河北以岭医药研究院有限公司 | 一种调节血脂、改善睡眠的中药组合物及其制备方法 |
CN102327574A (zh) * | 2011-06-20 | 2012-01-25 | 洪伟 | 一种用于治疗冠心病的复方制剂及其制备方法 |
CN105412271A (zh) * | 2015-11-19 | 2016-03-23 | 天津天狮生物发展有限公司 | 一种用于改善睡眠的组合物及其制备方法 |
CN108607091A (zh) * | 2016-12-12 | 2018-10-02 | 锡林郭勒盟肽好生物制品有限责任公司 | 降血压多肽草本固体饮料的配方及心肌肽粉制备方法 |
Non-Patent Citations (2)
Title |
---|
侯喜等: "益气活血养心安神方剂辅治扩张型心肌病对心肺功能的影响", 《临床合理用药杂志》 * |
汪芳: "《别让你的血管比你老》", 31 July 2018, 科学技术文献出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4708949A (en) | Therapeutic composition from plant extracts | |
CN101317615B (zh) | 一种银棘茶饮料及其制备方法 | |
CN102742691A (zh) | 具有降血压作用的保健茶饮品及制备方法 | |
CN107126485A (zh) | 一种辅助改善睡眠的中药组合物及其制备方法和应用 | |
CN1382022A (zh) | 用红藤叶萃取物治疗慢性静脉机能不全的方法 | |
CN102920806B (zh) | 安神降压中药茶 | |
CN107136370A (zh) | 一种具有抗肿瘤功效的中药发酵饮料及其制备方法 | |
CN1739389A (zh) | 益智冲剂及其制备工艺 | |
CN111686237A (zh) | 一种防治心血管疾病的心肌肽金丝小枣制剂及其制备方法 | |
CN104256618B (zh) | 一种降血糖的食品、保健品或药物组合物 | |
CN103599259B (zh) | 一种具有降血糖作用的傣药提取物制备及其应用 | |
CN108379500B (zh) | 一种养肝解酒醒酒防口臭的麦苗中药组合物及制备方法 | |
KR20010018271A (ko) | 심혈관 질환 치료제의 조성 및 그의 제조방법 | |
CN111840448B (zh) | 防皲裂复方中药脂质体的制备方法及其应用 | |
CN115006492B (zh) | 一种治疗失眠的中药组合物及其应用 | |
CN106728828A (zh) | 一种治疗冠心病的中药制剂及其制备工艺 | |
CN108042595B (zh) | 一种具有保健功能的组合物及其制备方法和应用 | |
CN108785649B (zh) | 一种用于压力型肥胖体重控制的组合物 | |
CN108379515B (zh) | 具有治疗心绞痛作用的药物及其制备方法 | |
CN108236714B (zh) | 缓解体力疲劳和辅助降血脂的组合物及其软胶囊 | |
CN114224973A (zh) | 一种治疗糖尿病酮症的中药组合物 | |
CN113456589A (zh) | 一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用 | |
CN113842431A (zh) | 一种具有强腰固肾、生精举阳功能的养生酒及其制备方法和应用 | |
CN105560733B (zh) | 一种保健酒 | |
CN115998814A (zh) | 一种复方替米考星注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200922 |